



The Hatter Cardiovascular Institute, UCL

WEBINAR SERIES: SGLT2 inhibitors & GLP-1 analogues in the management of type 2 diabetes and cardio-renal disease



FOR TRAINEES: *Cardiology *Diabetes *Nephrology

Meeting 1
1 hour

Consultant Views:
2nd July 2021 (12 noon)

1. Overview: How do these drugs affect cardiovascular, renal and metabolic medicine?

Prof Niko Marx, Aachen University Hospital, Aachen, Germany

2. How should the cardiologist manage the renal &/or patient with diabetes?

Prof Malcolm Walker, Consultant Cardiologist, UCLH, London

3. How should the nephrologist manage the cardiovascular and/or patient with diabetes?

Prof David Wheeler, Consultant Nephrologist, Royal Free Hospital, London

4. How should the diabetologist manage the renal &/or cardiovascular patient?

Prof Stephanie Baldeweg, Consultant Diabetologist, UCLH, London

5. Breakout Discussions by Trainees

***REGISTER:** <https://ucl.zoom.us/meeting/register/tJEtce-ujjMvG9Qu9ZfvbRh0uD5KzMYfNPgh>

Meeting 2
1 hour

SpR Views:
24th September 2021 (12 noon)

1. Emerging therapies affecting cardiovascular, renal and metabolic medicine?

Prof Mansoor Husain, University of Toronto, Toronto, Canada

2. SpR Case presentations: Out of my comfort zone!

(i) Cardiovascular – Dr Ali Rauf, Cardiology SpR

How do I handle a patient with renal/diabetic co-morbidities?

(ii) Renal – Dr Tamer Rezk, Nephrology SpR

How do I handle a patient with cardiac/diabetic co-morbidities?

(iii) Metabolic – Dr Eleni Armeni, Diabetes and Endocrinology SpR

How do I handle a patient with cardiac/renal co-morbidities?

5. Breakout Discussions by Trainees

***REGISTER:** <https://ucl.zoom.us/meeting/register/tJ0odeghpziGtVqtsVuljWJq8SlrqfoJTPU>